Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Terminated 6Completed 5Withdrawn 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Leiomyoma 5Menorrhagia 1Endometriosis 1

Interventions

Cyclophosphamide 1488Cisplatin 1410Paclitaxel 1316Radiotherapy 1259Carboplatin 1247Gemcitabine 1214Docetaxel 1110Bevacizumab 1029Fluorouracil 894Doxorubicin 786Dexamethasone 746Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 673Etoposide 673Irinotecan 634Filgrastim 621Cytarabine 584Leucovorin 578Nivolumab 557Vincristine 510Prednisone 474Cetuximab 464Bortezomib 457Erlotinib Hydrochloride 456Trastuzumab 448Methotrexate 437Lenalidomide 426Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Interventional × vilaprisan × Clear all
NCT03411980 2019-12-03

Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

Bayer

Phase 1 Completed
26 enrolled

Endometriosis, Leiomyoma

NCT02131662 2017-12-08

ASTEROID 1

Bayer

Phase 2 Completed
309 enrolled 24 charts

Leiomyoma

NCT03092999 2017-08-18

Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)

Bayer

Phase 1 Completed
36 enrolled

Leiomyoma

NCT02465814 2016-11-22

ASTEROID 2

Bayer

Phase 2 Completed
120 enrolled

Leiomyoma, Menorrhagia

NCT01816815 2014-04-21

Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670

Bayer

Phase 1 Completed
73 enrolled

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡